Tetrapeptide Ingredients TRIZ Cases

Oxetane substituents improve compound stability and enable oral administration, resolving delivery complexity and storage degradation issues.

Aromatic-cationic peptides preemptively shield renal microvasculature from reperfusion injury, ensuring sustained tissue perfusion after angioplasty.

Modulating steric and stereoelectronic effects in heterocyclic acyl hydrazone linkers improves plasma stability while maintaining efficient lysosomal cleavage.

Simplifying the complex macrocycle of Cyclotheonellazole A yields an analog that effectively inhibits Mpro and neutrophil elastase.

Quantify active caspase-4 and IL-1α cytokines to resolve missing biomarker information in lung cancer diagnosis.

Moderate potency MALT-1 inhibitors attenuate tumor growth by reprogramming regulatory T cells to secrete pro-inflammatory IFN-gamma.

Aromatic-cationic peptides stabilize the dystrophin-glycoprotein complex in muscle tissue.

A non-aqueous parenteral composition stabilizes carfilzomib without water.

A hemodynamic peptide comprising autophagy inhibiting amino acids modulates vascular permeability and fluid retention.

Pre-implantation factor peptides treat dystrophy by reducing fibrosis and side effects from current therapies.

Liraglutide and gefitinib repurposing addresses the lack of effective therapies by inhibiting inflammatory cytokines and reducing pulmonary fibrosis.

Trehalose stabilizes kappa opioid receptor agonists during storage, resolving the contradiction between long-term stability and oral bioavailability.

Nectin-4 antibody drug conjugate treats cisplatin-ineligible muscle invasive bladder cancer patients while maintaining eligibility for radical cystectomy.

Site-specific cysteine residues enable controlled dimerization, resolving random cross-linking heterogeneity and improving therapeutic efficacy.

Segmentation isolates peptides from organic acids during storage, preventing degradation while ensuring intestinal release.

DNA-templated synthesis generates macrocyclic libraries to discover kinase inhibitors with high specificity and low IC50 values.

Humanizing constant regions and maturing CDRs extends antibody half-life while reducing immunogenic side effects.

Treating alkylated cyclodextrin with phosphate-free activated carbon reduces chloride and color-forming impurities to extend active agent shelf-life.

Ugi-type synthesis of tubugis avoids toxic reagents while maintaining cytotoxic activity.

A tetrapeptide with sequence R-X1-X2-E inhibits VEGF-induced angiogenesis.

Replacing lithium hydroxide with alkoxymagnesium halides prevents beta-elimination impurities during glucuronide deprotection, boosting purity and yield.

Modified CCR5 inhibitors reduce inflammatory side effects while enhancing anti-cancer potency against resistant tumors.

Conjugating peptides with alkyl glycosides via linker amino acids reduces aggregation and immunogenicity while extending duration of action.

Aromatic-cationic peptides reduce atherosclerotic plaque size and cholesterol content, allowing higher statin dosages without side effects.

Glutamyl-aspartyl-proline stimulates lymphocyte proliferation and differentiation, restoring tissue-specific protein synthesis in age-related immune disorders.

Segmented nanocapsules decouple drug delivery from immune cell damage, reducing immunotoxicity while controlling tumor growth.

A site-specific antibody-drug conjugate uses a peptide-containing scaffold to attach therapeutic agents at defined locations on the targeting moiety.

Segmented BDNF tetra peptides improve blood-brain barrier permeability and plasma stability while maintaining neurotrophic activity.

A reverse thermal gel transitions from liquid to gel at body temperature to enable sustained drug release.

Tripeptide fluoromethylketone inhibitors block MALT1 proteolysis to overcome chemoresistance and induce apoptosis in ABC-DLBCL.

A CD20-targeted antibody-drug conjugate delivers cytotoxic agents to tumor cells via specific antigen binding.

Peptidomimetic compounds bridge target substrates and Ubr E3 ligases, overcoming compartmentalization limits of PROTACs.

A polypeptide regulates multiple genes across organs, treating inflammation and metabolic diseases while avoiding complex multi-drug development.

Aromatic-cationic peptide normalizes gene expression to reduce tumor severity while minimizing side effects from conventional treatments.

Aromatic-cationic peptides increase AGK expression, reducing cardiomyopathy severity and improving cardiac function in Sengers syndrome.

Interference peptides inhibit viral entry by blocking spike protein binding to transferrin receptors, addressing the lack of approved antiviral therapies.

Novel peptide compounds inhibit the NS3 protease, addressing limited efficacy of existing therapies by reducing viral load.

Aromatic sandwich cage inhibitors occupy the Kac-binding pocket of the YEATS2 YEATS domain to block histone acylation recognition.

Macrocyclic tetrapeptides achieve selective kappa opioid receptor antagonism to resolve off-target effects and limited duration of action in pain management.

Antibody-drug conjugate targets c-Kit using cleavable linker to deliver cytotoxic agents, overcoming drug resistance and adverse reactions.

Kappa opioid receptor agonists decrease circulating vasopressin levels to treat polycystic kidney disease.

Conjugated tubulysin analogs deliver cytotoxic activity to cancer cells via specific targeting moieties, resolving non-targeted delivery limitations.

TG2 inhibitors reduce mucus viscoelasticity to improve mucociliary clearance in respiratory diseases.

A self-immolative linker stabilizes antibody-drug conjugates via enzymatic cleavage.

Sulfamide linkers modify antibody conjugates to enhance hydrophobic payload solubility, reducing aggregation and improving the therapeutic index.